Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322587 | 0.88 | MAPT (0.51) | PARP1MAPTGRM5NPC1RAB9A | |
| SCHEMBL6322794 | 0.87 | NT5E (0.55) | MAPK1MAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL6322937 | 0.87 | CYP1A2 (0.48) | PARP1SMN1; SMN2NPC1RAB9AMAPK14 | |
| SCHEMBL6315634 | 0.87 | FLT3 (0.47) | PARP1MAPTSMN1; SMN2GRM5KDM4E | |
| SCHEMBL6319728 | 0.86 | TBK1 (0.52) | MAPK1SMN1; SMN2RAB9AKDM4EHTT | |
| SCHEMBL27591464 | 0.84 | MAPK14 (0.41) | PARP1MAPK1MAPTSMN1; SMN2GRM5 | |
| SCHEMBL6317501 | 0.84 | MAPT (0.53) | PARP1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6321264 | 0.84 | LMNA (0.55) | LMNA | |
| SCHEMBL6318091 | 0.82 | NPC1 (0.55) | MAPK1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL6316602 | 0.81 | MAPT (0.43) | PARP1MAPTSMN1; SMN2GRM5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| US-6872792-B2 | Metathesis polymerization adhesives and coatings | LORD CORPORATION (US) | 2005-03-29 | — | — | US | disclosed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| US-6800170-B2 | INCREASING THE BONDING STRENGTH TO SUBSTRATE, BY USING A POLYMERIZABLE MONOMER SELECTING FROM CYCLOBUTENE, NORBORNENE, AND A METALLIC COMPLEXES CATALYST TO FORM METATHESIS RING OPENING POLYMERIZATION | LORD CORPORATION | 2004-10-05 | — | — | US | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| US-20030230598-A1 | Metathesis polymerization adhesives and coatings | LORD CORPORATION | 2003-12-18 | — | — | US | disclosed |
| US-20030058812-A1 | Metathesis polymerization adhesives and coatings | LORD CORPORATION | 2003-03-27 | — | — | US | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003000764-A2 | METATHESIS POLYMERIZATION ADHESIVES AND COATINGS | LORD CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | PARP1 811/4885MAPK1 178/4885MAPT 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.